O’BrienE. Why ABPM should be mandatory in all trials of blood pressure–lowering drugs. Drug Information Journal. 2011;45(3):233–239.
2.
Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type diabetes. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). December 2008. Available athttp://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed March 6, 2012.
3.
CaveneyETurnerJR. Regulatory landscapes for future antidiabetic drug development (Part I): FDA guidance on assessment of cardiovascular risk. J Clin Studies. 2010:34–36.
